胰腺癌患者来源异种移植模型 z-bo 2020-12-25 331

　　Objective: To use the PDX model of pancreatic cancer to evaluate the therapeutic effects of clinical chemotherapy drugs and to screen individualized treatment plans.

　　Methods: Transplant fresh surgical specimens of pancreatic cancer subcutaneously into nude mice, establish a PDX model and pass it stably; use STR genotyping to detect the traceability of the tumor tissue of the PDX model; select three clinically used oxaliplatin, gemcitabine and irinotecan Two kinds of chemotherapeutics were treated and the tumor volume was measured; the TGD value mathematical model method was used, supplemented by plasma CA19-9 detection to evaluate the therapeutic effects of the three chemotherapeutics. Results: The traceability of the tumor tissue samples of the PDX model was 99%, which was consistent with the primary tumor; compared with the control group, the irinotecan group and the gemcitabine group had significant therapeutic effects (P=0.001), and gemcitabine The anti-tumor effect is more obvious; Irinotecan has the least toxic effect, followed by gemcitabine.

　　Conclusion: The PDX model of pancreatic cancer was successfully established and passaged stably. Through the TGD value mathematical model method, it was found that gemcitabine had the most significant effect in inhibiting tumor growth. It is recommended as the first choice for the personalized treatment of pancreatic cancer.